Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG

Eduardo Orihuela, Harry W. Herr, Willet F. Whitmore

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We reviewed 125 male patients treated with a six-week course of intravesical bacillus Calmette-Guerin (BCG) for superficial transitional cell cancer (TCC) of the bladder that was associated with mucosal involvement of the prostatic urethra in 15 cases. In 13 of these 15 cases, there was a sustained complete response in both the bladder and the prostate. Among the other 110 patients, in 14 TCC developed in the prostate from one to fifty-three (mean 15) months after completion of BCG. Six of these 14 had had complete response in the bladder. Recurrent TCC in the prostate was .seen in only 4 percent and 6 percent of patients who had prostatic urethritis on cystos-copy and prostatic granulomas on biopsy, respectively. In contrast, recurrence was observed in 14 percent of those without urethritis and in 44 percent of those without granulomas. Transurethral resection of the prostate (TURP) prior to BCG did not appear to influence tumor recurrence in the prostate. However, after BCG, 3 patients with recurrent TCC in the prostate had complete local response after TURP alone. Further, prostatic urethritis (73%) and prostatic granulomas (60%) were more frequent among patients who had TURP prior to BCG than in those without TURP (33 % and 27 %, respectively). Superficial TCC of the bladder associated with mucosal involvement of the prostatic urethra can be treated successfully with intravesical BCG. In addition, our results suggest that intravesical BCG has a prophylactic effect on tumor recurrence in the prostate, and that TURP may have an important role bit removing present disease and by facilitating the development of an effective biologic response to BCG in the prostate. TCC in the prostate is a significant cause of relapse, and frequent surveillance of the prostatic urethra should be performed in conservatively treated patients with superficial bladder cancer.

Original languageEnglish (US)
Pages (from-to)231-237
Number of pages7
JournalUrology
Volume34
Issue number5
DOIs
StatePublished - 1989

Fingerprint

Transitional Cell Carcinoma
Urethra
Mycobacterium bovis
Transurethral Resection of Prostate
Prostate
Urethritis
Granuloma
Urinary Bladder Neoplasms
Recurrence
Prostatic Neoplasms
Urinary Bladder
Neoplasms
Conservative Treatment
Biopsy

ASJC Scopus subject areas

  • Urology

Cite this

Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG. / Orihuela, Eduardo; Herr, Harry W.; Whitmore, Willet F.

In: Urology, Vol. 34, No. 5, 1989, p. 231-237.

Research output: Contribution to journalArticle

Orihuela, Eduardo ; Herr, Harry W. ; Whitmore, Willet F. / Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG. In: Urology. 1989 ; Vol. 34, No. 5. pp. 231-237.
@article{d38fc8f3f53f460d8f0aedbb7db2b8cc,
title = "Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG",
abstract = "We reviewed 125 male patients treated with a six-week course of intravesical bacillus Calmette-Guerin (BCG) for superficial transitional cell cancer (TCC) of the bladder that was associated with mucosal involvement of the prostatic urethra in 15 cases. In 13 of these 15 cases, there was a sustained complete response in both the bladder and the prostate. Among the other 110 patients, in 14 TCC developed in the prostate from one to fifty-three (mean 15) months after completion of BCG. Six of these 14 had had complete response in the bladder. Recurrent TCC in the prostate was .seen in only 4 percent and 6 percent of patients who had prostatic urethritis on cystos-copy and prostatic granulomas on biopsy, respectively. In contrast, recurrence was observed in 14 percent of those without urethritis and in 44 percent of those without granulomas. Transurethral resection of the prostate (TURP) prior to BCG did not appear to influence tumor recurrence in the prostate. However, after BCG, 3 patients with recurrent TCC in the prostate had complete local response after TURP alone. Further, prostatic urethritis (73{\%}) and prostatic granulomas (60{\%}) were more frequent among patients who had TURP prior to BCG than in those without TURP (33 {\%} and 27 {\%}, respectively). Superficial TCC of the bladder associated with mucosal involvement of the prostatic urethra can be treated successfully with intravesical BCG. In addition, our results suggest that intravesical BCG has a prophylactic effect on tumor recurrence in the prostate, and that TURP may have an important role bit removing present disease and by facilitating the development of an effective biologic response to BCG in the prostate. TCC in the prostate is a significant cause of relapse, and frequent surveillance of the prostatic urethra should be performed in conservatively treated patients with superficial bladder cancer.",
author = "Eduardo Orihuela and Herr, {Harry W.} and Whitmore, {Willet F.}",
year = "1989",
doi = "10.1016/0090-4295(89)90314-2",
language = "English (US)",
volume = "34",
pages = "231--237",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG

AU - Orihuela, Eduardo

AU - Herr, Harry W.

AU - Whitmore, Willet F.

PY - 1989

Y1 - 1989

N2 - We reviewed 125 male patients treated with a six-week course of intravesical bacillus Calmette-Guerin (BCG) for superficial transitional cell cancer (TCC) of the bladder that was associated with mucosal involvement of the prostatic urethra in 15 cases. In 13 of these 15 cases, there was a sustained complete response in both the bladder and the prostate. Among the other 110 patients, in 14 TCC developed in the prostate from one to fifty-three (mean 15) months after completion of BCG. Six of these 14 had had complete response in the bladder. Recurrent TCC in the prostate was .seen in only 4 percent and 6 percent of patients who had prostatic urethritis on cystos-copy and prostatic granulomas on biopsy, respectively. In contrast, recurrence was observed in 14 percent of those without urethritis and in 44 percent of those without granulomas. Transurethral resection of the prostate (TURP) prior to BCG did not appear to influence tumor recurrence in the prostate. However, after BCG, 3 patients with recurrent TCC in the prostate had complete local response after TURP alone. Further, prostatic urethritis (73%) and prostatic granulomas (60%) were more frequent among patients who had TURP prior to BCG than in those without TURP (33 % and 27 %, respectively). Superficial TCC of the bladder associated with mucosal involvement of the prostatic urethra can be treated successfully with intravesical BCG. In addition, our results suggest that intravesical BCG has a prophylactic effect on tumor recurrence in the prostate, and that TURP may have an important role bit removing present disease and by facilitating the development of an effective biologic response to BCG in the prostate. TCC in the prostate is a significant cause of relapse, and frequent surveillance of the prostatic urethra should be performed in conservatively treated patients with superficial bladder cancer.

AB - We reviewed 125 male patients treated with a six-week course of intravesical bacillus Calmette-Guerin (BCG) for superficial transitional cell cancer (TCC) of the bladder that was associated with mucosal involvement of the prostatic urethra in 15 cases. In 13 of these 15 cases, there was a sustained complete response in both the bladder and the prostate. Among the other 110 patients, in 14 TCC developed in the prostate from one to fifty-three (mean 15) months after completion of BCG. Six of these 14 had had complete response in the bladder. Recurrent TCC in the prostate was .seen in only 4 percent and 6 percent of patients who had prostatic urethritis on cystos-copy and prostatic granulomas on biopsy, respectively. In contrast, recurrence was observed in 14 percent of those without urethritis and in 44 percent of those without granulomas. Transurethral resection of the prostate (TURP) prior to BCG did not appear to influence tumor recurrence in the prostate. However, after BCG, 3 patients with recurrent TCC in the prostate had complete local response after TURP alone. Further, prostatic urethritis (73%) and prostatic granulomas (60%) were more frequent among patients who had TURP prior to BCG than in those without TURP (33 % and 27 %, respectively). Superficial TCC of the bladder associated with mucosal involvement of the prostatic urethra can be treated successfully with intravesical BCG. In addition, our results suggest that intravesical BCG has a prophylactic effect on tumor recurrence in the prostate, and that TURP may have an important role bit removing present disease and by facilitating the development of an effective biologic response to BCG in the prostate. TCC in the prostate is a significant cause of relapse, and frequent surveillance of the prostatic urethra should be performed in conservatively treated patients with superficial bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=0024467924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024467924&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(89)90314-2

DO - 10.1016/0090-4295(89)90314-2

M3 - Article

VL - 34

SP - 231

EP - 237

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -